High survival rate with the LMT-89 regimen in lymphoblastic lymphoma (LL), but not in T-cell acute lymphoblastic leukemia (T-ALL).

The most appropriate treatment for lymphoblastic lymphomas (LL) remains uncertain. We treated 27 patients with newly diagnosed LL according to an LMT-89 protocol, which is a modified version of the LMT-81 protocol previously reported in pediatric patients. The median age was 31 years.

Prognostic value of the age-adjusted International Prognostic Index in chemosensitive recurrent or refractory non-Hodgkin's lymphomas treated with high-dose BEAM therapy and autologous stem cell transplantation.

High-dose therapy (HDT) is now recommended for patients under 60 years of age with chemosensitive relapsed aggressive non-Hodgkin's lymphoma. However, approximately half of these patients will be cured by HDT. Prognostic factors are needed to predict which patients with chemosensitive lymphoma to second-line therapy could benefit from HDT.

[Evaluation of a new form of care: the permanently maintained health care facility at the university hospital center in Nantes].

Considering the consequences of social instability within the health care system has become a public health priority. Each public hospital center in France is obliged to create a unit for welcoming impoverished and vulnerable people (Permanently Maintained Health Care Facilities). The university hospital in Nantes opened a socio-medical out-patient consultation service in November 1999 with the main objective being to bring these patients back into the usual ambulatory care system.